Competitor Analysis: RSV Vaccines and Therapeutics

  • June 2012
  • -
  • La Merie Publishing
  • -
  • 30 pages

Competitor Analysis: Respiratory Syncytial Virus (RSV) Vaccines and Therapeutics

The present Competitive Intelligence Report about RSV Vaccines & Therapeutics provides a competitor evaluation in the field of prophylactic vaccines and therapeutic antibodies, small molecules and RNAi against infection with respiratory syncytial virus (RSV) as of June 2012. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Respiratory syncytial virus (RSV) infection, which manifests primarily as bronchiolitis and/or viral pneumonia, is the leading cause of lower respiratory tract infection in infants and young children. In the US, RSV LRT infection develops annually in 4-5 million children, and more than 125,000 children are admitted per year for RSV-related illness. RSV disease is the no.1 cause of hospitalization in babies under a year of age in the US. While a monoclonal antibody is commercially available to help prevent RSV disease in infants and children at high risk for severe lung disease from RSV, a RSV vaccine still is not on the market. A number of RSV vaccine candidates have entered clinical development and further are to follow. Also, next generation antibodies against RSV with improved features are in the development pipeline as well as new therapies based on silencing RSV RNA or inhibiting key targets of the virus.
The report includes a compilation of currently active projects in development of vaccines, antibodies, small molecules and small interfering RNA (siRNA) targeting respiratory syncytial virus for prophylaxis and treatment of RSV infections. In addition, the report lists company-specific R&D pipelines of RSV Vaccines & Therapeutics. Competitor projects are listed in a tabular format providing information on:
-Drug Codes,
-Target / Mechanism of Action,
-Class of Compound,
-Company,
-Product Category,
-Indication,
-R&D Stage and
-additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table Of Contents

Competitor Analysis: RSV Vaccines and Therapeutics
 Index

-RSV Vaccines
-Antibody-Based RSV Therapeutics
-Other Biologics as RSV Therapeutics
-Small Molecule RSV Therapeutics
-Corporate RSV Vaccines and Therapeutics RandD Pipeline
-About La Merie

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Analysis of the Global Vaccines Delivery Market : Innovative Technologies and Future Trends for Stakeholders

Analysis of the Global Vaccines Delivery Market : Innovative Technologies and Future Trends for Stakeholders

  • $ 6 500
  • Industry report
  • March 2015
  • by Frost & Sullivan

Methodology The analysis in this research service is based on the following: •Information collected through discussions with market participants. •Information from secondary pharmaceutical companies, ...

Meningococcal Vaccines Market (Polysaccharide, Conjugate, Combination and Men B Vaccines, along with Pipeline Analysis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022

Meningococcal Vaccines Market (Polysaccharide, Conjugate, Combination and Men B Vaccines, along with Pipeline Analysis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022

  • $ 4 795
  • Industry report
  • April 2015
  • by Transparency Market Research

Meningococcal disease, especially meningococcal meningitis, is one of the most catastrophic infections among individuals or communities. Several meningococcal serogroups have been identified till date, ...

Vaccine Market by Technology, Type, End User, Disease Indication - Forecasts to 2019

Vaccine Market by Technology, Type, End User, Disease Indication - Forecasts to 2019

  • $ 4 650
  • Industry report
  • January 2015
  • by MarketsandMarkets

The vaccines market is expected to reach $57,885.4 million by 2019 from $33,140.6 million in 2014, at a CAGR of 11.8%. The global vaccines market is categorized on the basis of type, technology, disease ...


Download Unlimited Documents from Trusted Public Sources

Biopharmaceutical Market in the US

  • May 2015
    3 pages
  • Vaccine  

    Antibody  

    Antigen  

  • United States  

View report >

Global Vaccine Industry

  • May 2015
    72 pages
  • Vaccine  

  • United States  

    World  

View report >

Pathology Description in the US

  • May 2015
    22 pages
  • Diabetes  

    Vaccine  

  • United States  

View report >

Antibody Industry

17 days ago

Related Market Segments :

Vaccine

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.